Trial · NCT04913103
Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL
NCT04913103, Phase 2, Not yet recruiting, Czech Lymphoma Study Group
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL. Trials, record NCT04913103. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04913103
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL
- NCT number
- NCT04913103
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 21 participants, estimated
- Lead sponsor
- Czech Lymphoma Study Group
- Conditions
- Lymphoma, Mantle-Cell
- Interventions
- Polatuzumab vedotin, Bendamustine Hydrochloride, Rituximab
- First posted
- 2021-06-04
- Last updated
- 2021-06-04
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) | 4 years | evaluation of the efficacy of the combination of polatuzumab vedotin plus bendamustine and rituximab (BR) with respect to progression-free survival (PFS) |
| Secondary | overall response rate (ORR) | 4 years | efficacy of polatuzumab vedotin plus BR with respect to overall response rate |
| Secondary | duration of response (DoR) | 4 years | efficacy of PV plus BR with respect to duration of response |
| Secondary | event free survival (EFS) | 4 years | efficacy of PV plus BR with respect to event free survival |
| Secondary | overall survival (OS) | 4 years | efficacy of PV plus BR with respect to overall survival |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04913103
GET https://conductscience.org/api/trials/v1/NCT04913103/registered